Article Text
Statistics from Altmetric.com
The papers compiled in this supplement of theAnnals of the Rheumatic Diseases constitute summaries of presentations at the first International Symposium on “Advances in Targeted Therapies—TNFα Blockade in Clinical Practice”, which was held in March 1999. As such they represent the state of the art on the biology, mechanisms of action and pathophysiology of TNFα as well as the current knowledge on means and consequences of blocking this important cytokine.
We are grateful to Drs Crofford, Feldmann, Klareskog, Lipsky, Maini, Moreland and Weinblatt, the members of the Advisory Board of the Symposium, for …
Footnotes
This supplement was made possible by unrestricted educational grants from Amgen (USA), Centocor (USA), Immunex (USA), Knoll (Germany), Schering-Plough (USA), and Wyeth-Ayerst (USA)
* The Conference was organised under the sole responsibility of the Departments of Rheumatology of the Universities of Erlangen, Leiden and Vienna in collaboration with an Advisory Board consisting of the above mentioned colleagues from Departments of Rheumatology of several other US and European Universities. The following companies provided unrestricted educational grants for the organisation of this Conference: Amgen, Centocor, Immunex, Knoll, Schering-Plough, Wyeth-Ayerst. Pharmaceutical industry had no part in the decisions regarding the specific programme and, with the exception of few observers, participants were selected and solely invited by the Organising Committee. Several members of the Advisory Board and the members of the Organising Committee have obtained experience in the use of TNF blocking compounds in the course of their participation in clinical studies on TNF blocking agents (for which the costs were defrayed by industry).